argenx SE (NASDAQ:ARGX) Shares Bought by Farther Finance Advisors LLC

Farther Finance Advisors LLC grew its position in shares of argenx SE (NASDAQ:ARGX) by 38.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 76 shares of the company’s stock after purchasing an additional 21 shares during the quarter. Farther Finance Advisors LLC’s holdings in argenx were worth $47,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. FMR LLC grew its holdings in shares of argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after acquiring an additional 1,265,486 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of argenx by 0.4% in the 3rd quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock worth $1,343,797,000 after acquiring an additional 10,975 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of argenx by 13.0% in the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after acquiring an additional 55,617 shares during the last quarter. Alkeon Capital Management LLC grew its holdings in shares of argenx by 15.0% in the 3rd quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company’s stock worth $187,018,000 after acquiring an additional 45,000 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in shares of argenx by 27.0% in the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock worth $185,821,000 after buying an additional 64,183 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $615.02 on Monday. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21. The company has a market capitalization of $37.37 billion, a PE ratio of -698.89 and a beta of 0.59. The company has a fifty day moving average of $634.69 and a 200-day moving average of $600.25.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, equities analysts forecast that argenx SE will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

ARGX has been the subject of several recent analyst reports. HC Wainwright raised their target price on argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Piper Sandler lifted their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research report on Tuesday, January 7th. Wedbush reaffirmed an “outperform” rating and issued a $655.00 price target on shares of argenx in a research report on Tuesday, December 3rd. Oppenheimer lifted their price objective on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company lifted their price objective on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.